FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
1. FDA found Eli Lilly's promotional video misleading regarding safety risks. 2. Zepbound and Mounjaro have serious health warnings that were underemphasized. 3. Eli Lilly has 15 days to respond to the FDA's findings on the video. 4. Currently, LLY shares are up 2.38% at $766.02. 5. The video featured biased perspectives from paid consultants minimizing risks.